Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors

Documenti analoghi

• Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
  di: Balzarini, J, et al.
  Pubblicazione: (1994)
• Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
  di: Chunlin Zhuang, et al.
  Pubblicazione: (2020-06-01)
• Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
  di: Zhuang, Chunlin, et al.
  Pubblicazione: (2020)
• Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.
  di: Pelemans, H, et al.
  Pubblicazione: (1997)
• Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
  di: Zhao, Chenglong, et al.
  Pubblicazione: (2020)